Figure 1

Frequency of CD3⁺ T cells and CD8⁺ T cells detected by flow cytometry. (A) Gating strategy for identifying CD3⁺ T cells and their subpopulations by flow cytometry. (B) Comparison of the frequency distribution and pairwise distribution of CD3⁺ T cells and CD8⁺ T cells in the peripheral blood of the Normal-B group (n = 16), Tumor-B group (n = 46), peri-tumor group (n = 17), and Tumor group (n = 20). (C) Frequency distribution and pairwise comparison of CD8⁺ T cells in peripheral blood in the Normal-B group (n = 16), Tumor-B group (n = 46), peri-tumor group (n = 17), and Tumor group (n = 20). (D) Typical staining of CD352, TIM3, CD39, PD1, and NRP1 expression in CD8⁺ T cells in the Normal-B, Tumor-B, and Tumor groups. (E-I) Frequency plots of CD352, TIM3, CD39, PD1, and NRP1 expression in CD8⁺ T cells in the Normal-B, Tumor-B, peri-tumor, and Tumor groups. Normal-B, Tumor-B, peri-tumor, and Tumor groups are peripheral blood PBMC group of healthy volunteers, peripheral blood PBMC group of patients with non-small cell lung cancer (NSCLC), paracancerous tissue group of patients with NSCLC, and cancerous tissue group of patients with NSCLC, respectively. ns, not statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001.